Enterprise Value
154.1M
Cash
179.3M
Avg Qtr Burn
-21.03M
Short % of Float
4.65%
Insider Ownership
9.99%
Institutional Own.
28.03%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMP360 Details Treatment Resistant Depression | Phase 3 Data readout | |
RL-007 Details Cognitive Dysfunction, Schizophrenia | Phase 2b Data readout | |
BPL-003 (Intranasal 5-MeO-DMT) Details Treatment Resistant Depression | Phase 2b Data readout | |
COMP360 Details Post-traumatic stress disorder | Phase 2 Data readout | |
GRX-917 Details Anxiety Disorders | Phase 2 Update | |
BPL-003 (Intranasal 5-MeO-DMT) Details Alcohol use disorder | Phase 2a Data readout | |
ELE-101 Details Major depressive disorder | Phase 1/2 Data readout | |
Ibogaine (DMX-1002) Details Opioid use disorder | Phase 1/2 Update | |
VLS-01 Details Treatment Resistant Depression | Phase 1b Data readout | |
EMP-01 (3,4-methylenedioxy-methamphetamine [MDMA] derivative) Details Post-traumatic stress disorder | Phase 1 Update | |
PCN-101 (R-Ketamine) Details Treatment Resistant Depression | Phase 1 Update | |
PCN-101 Details Treatment Resistant Depression | Failed Discontinued |